Critical Care Antiarrhythmic Drugs Market | 2021 Size, Growth, Share, Cap, Regional Analysis With Global Industry Forecast To 2027, The global critical care antiarrhythmic drugs market size is projected to reach USD 1,319.7 million by 2027, exhibiting a CAGR of 5.6% during the forecast period. Increasing prevalence of cardiovascular diseases (CVDs) around the world will be a major growth determinant for this market, highlights Fortune Business Insights™ in its report, titled Critical Care Antiarrhythmic Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Beta Blockers, Calcium Channel Blockers, Sodium Channel Blockers, Potassium Channel Blockers, and Others), By Disease Type (Supraventricular Arrhythmias, Ventricular Arrhythmias, and Others), and Regional Forecast, 2020-2027.
List of Key Companies Covered in the Market for Critical Care Antiarrhythmic Drugs:
- Amomed Pharma GmbH (Vienna, Austria)
- Mayne Pharma (Salisbury South, Australia)
- Sanofi (Paris, France)
- Mylan N.V. (Pennsylvania, U.S.)
- Pfizer Inc. (New York, U.S.)
- Upsher-Smith Laboratories, LLC. (Minnesota, U.S.)
- GlaxoSmithKline plc (London, U.K.)
- Baxter International Inc. (Deerfield, U.S.)
- Novartis AG (Basel, Switzerland)
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/critical-care-antiarrhythmic-drugs-market-104703
Critical Care Antiarrhythmic Drugs Market Analysis 2021:
According to the World Health Organization (WHO), CVDs are the premier cause of global deaths, killing nearly 17.9 million people worldwide in 2016. Atrial fibrillation (AF) is the most frequent and the most commonly observed CVD. For example, the American Heart Association estimates that AF affects around 2.2 million people in the United States.
More importantly, the incidence of AF is steadily rising. A study conducted by the Erasmus Medical Center in the Netherlands found that approximately 17.9 million people across Europe will be afflicted by AF in 2060. A similar epidemiological study conducted by researchers at the University of Arkansas revealed that in the US, between 6 million and 12 million people will suffer from AF by 2050. These projections indicate a steady rise in the demand for critical care antiarrhythmic drugs in the forthcoming decades as cardiac arrhythmia can turn fatal if not treated with effective medication in time.
Growing Importance of Heart Health amid COVID-19 to Boost the Market
The COVID-19 pandemic has reiterated the importance of maintaining heart health as patients suffering from heart-related comorbidities have been found to be at high risk of contracting the coronavirus. Early evidence from China’s Hubei and Wuhan provinces shows that 16.7% of the hospitalized patients and 44.4% of patients in intensive care units (ICUs) had cardiac arrhythmia. Another study conducted by researchers from the Perelman School of Medicine at the University of Pennsylvania in July 2020 revealed that the onset of the COVID-19 infection was associated with a high incidence of cardiac arrhythmias in patients. While the coronavirus is not solely responsible for the occurrence of cardiac abnormalities, the infection, in many cases, has worsened the preexisting conditions, leading to higher mortality rates among patients with chronic heart diseases. The coronavirus has, thus, heightened the adoption of critical care anti-arrhythmogenic drugs worldwide. The global market has, as a result, registered a CAGR of 12.9% in 2020.
Out research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers & acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.
Click here to get the short-term and long-term impact of COVID-19 on this market.
Critical Care Antiarrhythmic Drugs Highlights of the Report:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.
- Product Development/Innovation: Detailed insights on the upcoming technologies, RandD activities, and product launches in the market
- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market
Detailed Table of Content:
1 Critical Care Antiarrhythmic Drugs Market Overview
1.1 Critical Care Antiarrhythmic Drugs Product Overview
1.2 Critical Care Antiarrhythmic Drugs Market Segment by Type
1.3 Global Critical Care Antiarrhythmic Drugs Market Size by Type (2015-2027)
1.3.1 Global Critical Care Antiarrhythmic Drugs Market Size Overview by Type (2015-2027)
1.3.2 Global Critical Care Antiarrhythmic Drugs Historic Market Size Review by Type (2015-2021)
184.108.40.206 Global Critical Care Antiarrhythmic Drugs Sales Market Share Breakdown by Type (2015-2027)
220.127.116.11 Global Critical Care Antiarrhythmic Drugs Market Share Breakdown by Type (2015-2027)
18.104.22.168 Global Critical Care Antiarrhythmic Drugs Average Selling Price (ASP) by Type (2015-2027)
1.3.3 Global Critical Care Antiarrhythmic Drugs Market Size Forecast by Type (2021-2027)
22.214.171.124 Global Critical Care Antiarrhythmic Drugs Sales Market Share Breakdown by Application (2021-2027)
126.96.36.199 Global Critical Care Antiarrhythmic Drugs Revenue Market Share Breakdown by Application (2021-2027)
188.8.131.52 Global Critical Care Antiarrhythmic Drugs Average Selling Price (ASP) by Application (2021-2027)
1.4 Key Regions Market Size Segment by Type (2015-2021)
1.4.1 North America Critical Care Antiarrhythmic Drugs Sales Breakdown by Type (2015-2027)
1.4.2 Europe Critical Care Antiarrhythmic Drugs Sales Breakdown by Type (2015-2027)
1.4.3 Asia-Pacific Critical Care Antiarrhythmic Drugs Sales Breakdown by Type (2015-2027)
1.4.4 Latin America Critical Care Antiarrhythmic Drugs Sales Breakdown by Type (2015-2027)
1.4.5 Middle East and Africa Critical Care Antiarrhythmic Drugs Sales Breakdown by Type (2015-2027)
2 Global Critical Care Antiarrhythmic Drugs Market Competition by Company
2.1 Global Top Players by Critical Care Antiarrhythmic Drugs Sales (2015-2021)
2.2 Global Top Players by Critical Care Antiarrhythmic Drugs Revenue (2015-2021)
2.3 Global Top Players Critical Care Antiarrhythmic Drugs Average Selling Price (ASP) (2015-2021)
2.4 Global Top Company Critical Care Antiarrhythmic Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Critical Care Antiarrhythmic Drugs Market Competitive Situation and Trends
2.5.1 Critical Care Antiarrhythmic Drugs Market Growth Rate (2015-2021)
2.5.2 Global 5 and 10 Largest Company by Critical Care Antiarrhythmic Drugs Sales and Revenue in 2019
2.6 Global Top Company by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Critical Care Antiarrhythmic Drugs as of 2019)
2.7 Date of Key Company Enter into Critical Care Antiarrhythmic Drugs Market
2.8 Key Company Critical Care Antiarrhythmic Drugs Product Offered
2.9 Mergers and Acquisitions, Expansion
3 Global Critical Care Antiarrhythmic Drugs Status and Outlook by Region (2015-2027)
3.1 Global Critical Care Antiarrhythmic Drugs Market Size and CAGR by Region: 2015 VS 2021 VS 2027
3.2 Global Critical Care Antiarrhythmic Drugs Market Size Market Share by Region (2015-2021)
3.2.1 Global Critical Care Antiarrhythmic Drugs Sales Market Share by Region (2015-2021)
3.2.2 Global Critical Care Antiarrhythmic Drugs Revenue Market Share by Region (2015-2021)
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/critical-care-antiarrhythmic-drugs-market-104703
Fortune Business Insights follows a robust research methodology that involves data triangulation based on top-down, bottom-up approaches, and validation of the estimated market numbers through primary research. The information used to estimate the market size and forecast for various segments at the global, regional, and country level is derived from the most credible published sources and through interviews with the right stakeholders.
Growth rate or CAGR exhibited by a market for a certain forecast period is calculated on the basis of various factors and their level of impact on the market. These factors include market drivers, restraints, industry challenges, market and technological developments, market trends, etc.
Reasons to Purchase this Report:
- Estimates Critical Care Antiarrhythmic Drugs trends with SWOT analysis.
- Detailed business profiles including product offerings, recent developments, key financial information, and strategies employed by main market players.
- Analysis of various regions and countries that includes the demand and supply based actions, which consequently have a major influence on the market’s expansion.
- Market dynamics and opportunities for growth for players in the near future.
- Competitive landscape describing the market revenue shares of key players.
- Market segmentation analysis that deals with quantitative and qualitative research, discussing the influence of policy-based and economical aspects.
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245